GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are Dental Pulp Stem Cells?

Dental pulp stem cells (DPSCs) are adult stem and stromal cells found in the soft tissue inside permanent teeth. Researchers can isolate and grow them in a laboratory. Under experimental conditions, they can form dentin-producing cells and dentin- and pulp-like tissue. They were first described in 2000 using human wisdom-tooth pulp and transplantation experiments in mice PMC17626.

DPSCs are being studied for repairing the inside of a tooth and tissues damaged by periodontitis. Repairing these tissues is not the same as growing a complete replacement tooth. Human studies offer early signals of benefit, but the cells, procedures, and results vary substantially.

What Are Dental Pulp Stem Cells?

Where dental pulp stem cells are found

The pulp contains blood vessels, nerves, connective tissue, and several kinds of cells. DPSCs are not all the cells in that space. A 2003 study identified a selected population associated with blood vessels, supporting the idea of a perivascular niche 12674330.

Researchers usually obtain pulp from extracted teeth, often wisdom teeth or teeth removed for orthodontic reasons. In the original study, donors were aged 19 to 29. Researchers opened the teeth, removed the pulp, separated cells with enzymes, and grew colonies in culture PMC17626. This does not mean a healthy tooth should be removed just to collect cells.

Collection is only the first step. In the 2017 Japanese pulp-regeneration pilot, researchers expanded a selected population from each patient’s own extracted tooth under good manufacturing practice conditions and checked the cells for contamination and chromosome abnormalities PMC5345141. The 2025 periodontal report instead used lab-expanded cells from donors PMC12311062.

DPSCs and other dental stem cells

The cell’s tissue of origin matters. Stem cells from human exfoliated deciduous teeth (SHED) come from primary teeth, not permanent-tooth pulp. Their original 2003 description included cell-culture and mouse experiments, not a treatment trial in children PMC156282.

Five commonly studied dental stem and progenitor cell populations
Name Tissue of origin
DPSCs Pulp of permanent teeth
SHED Pulp of shed primary teeth
Periodontal ligament stem cells (PDLSCs) Ligament around the tooth root
Stem cells from the apical papilla (SCAP) Soft tissue at the tip of a developing root
Dental follicle progenitor cells (DFPCs) Tissue surrounding a developing tooth

This classification describes different populations, not interchangeable treatments PMC2830488. A result involving SHED or periodontal ligament cells should not be presented as proof that a permanent-tooth DPSC product works.

What makes DPSCs different from ordinary pulp cells

In the original experiments, selected pulp cells adhered to plastic, formed colonies, and produced dentin- and pulp-like tissue after transplantation with a ceramic carrier into immunocompromised mice PMC17626. That is evidence of regenerative potential under those conditions, not proof that an injection can rebuild a patient’s tooth.

A widely used 2006 International Society for Cellular Therapy framework characterizes cultured mesenchymal stromal cells by plastic adherence, a defined surface-marker pattern, and bone, fat, and cartilage differentiation in laboratory tests. The marker pattern includes CD73, CD90, and CD105 and absence of specified blood-cell markers 16923606. These are identity criteria, not a test of clinical effectiveness.

DPSC preparations are heterogeneous. In the original study, pulp cells and bone marrow cells behaved differently in the same differentiation experiments; the pulp cells did not form fat cells under the tested conditions PMC17626. A product’s name alone therefore does not establish its composition, potency, or equivalence to another preparation.

What human studies show

The studies below illustrate three different approaches: cultured cells for pulp repair, mixed pulp micrografts during periodontal surgery, and donor-cell injections after periodontal cleaning. They are selected examples, not an exhaustive inventory of human dental stem-cell research. Their outcomes cannot be combined into a single success rate.

Selected human reports involving DPSCs or DPSC-rich preparations
Report and design Cells and procedure Findings and limits
Nakashima et al., 2017, Japan Uncontrolled pilot in 5 adults with irreversible pulpitis. Autologous mobilized DPSCs, the growth factor G-CSF, and an atelocollagen scaffold were placed into teeth after pulp removal. Positive electric pulp responses and MRI findings suggested tissue recovery. Imaging suggested dentin formation in 3 of 5 cases. Main safety assessment: 24 weeks, with some imaging extending to 32 weeks. No transplantation-related adverse events were reported during the 24-week safety follow-up. There was no randomized comparison PMC5345141.
Ferrarotti et al., 2018, Italy Randomized trial in 29 adults with periodontal intrabony defects: 15 received autologous DPSC-rich micrografts on collagen and 14 received collagen alone during periodontal surgery. At 12 months, probing-depth reduction was 4.9 versus 3.4 mm, attachment gain 4.5 versus 2.9 mm, and radiographic bone-defect fill 3.9 versus 1.6 mm. This was a small, single-center trial of mixed micrografts, not purified cultured DPSCs. The abstract does not provide a detailed adverse-event account 29779220.
Liu et al., 2025, China One publication reporting two randomized trials: a 96-person investigator-initiated trial and a 36-person phase I trial. Allogeneic DPSCs or saline were injected into local periodontal defects after scaling and root planing. Dose-finding included 1×106 to 1×107 cells per tooth. Follow-up was 6 months. The report did not establish a clear overall benefit on the main attachment-loss measure. It reported greater bone-defect-depth improvement and a favorable post hoc stage III attachment result. No serious adverse events were reported, but mild events occurred. The pooled subgroup analysis needs confirmation PMC12311062.

Irreversible pulpitis means inflammation of the pulp that is not expected to heal; it is not simply another name for a dead nerve. In the 2017 pilot, the diseased pulp was removed before cell transplantation. Electric pulp testing measures a sensory response, and MRI measures tissue signal. Neither result alone proves that a completely normal pulp has been restored PMC5345141.

Periodontal probing depth measures the depth of the pocket beside a tooth. Clinical attachment measurements assess loss or gain of support around the root; radiographic bone-defect measurements assess a different part of the response. None is a count of teeth regrown.

The 2025 report used allogeneic rather than autologous cells. Its reported bone-defect-depth improvement was 0.30 mm with cells versus 0.04 mm with saline. In a post hoc stage III analysis, attachment improvement was 1.67 versus 1.03 mm. Those are different outcomes from different analyses; the subgroup result should not be substituted for the overall primary result PMC12311062.

These dental protocols delivered cells locally, not by intravenous infusion. They tested pulp repair or periodontal measurements, not whole-tooth replacement. Their short follow-up and small or heterogeneous populations cannot settle durability or uncommon harms.

What remains unproven

The human reports summarized here do not establish that DPSCs can regrow a complete missing tooth, replace routine root-canal or periodontal care, or provide anti-aging benefits. They also cannot justify using an intravenous DPSC infusion for unrelated conditions such as arthritis or diabetes.

A tooth needs more than pulp: enamel, dentin, a root, and supporting tissues have to develop and function together. Whole-tooth regeneration is a different research problem from improving attachment around an existing tooth. In the studies above, no complete replacement tooth was grown.

Approval and clinic registration are different

Approval of one cell therapy does not approve every product carrying the same broad cell label. For example, the FDA approved Ryoncil in December 2024 for steroid-refractory acute graft-versus-host disease in children aged 2 months and older. It uses donor bone marrow-derived mesenchymal stromal cells, not dental pulp cells, and its approval does not cover dental repair Fda approves first mesenchymal stromal cell therapy treat steroid refractory acute graft versus host.

No DPSC product was identified in the FDA’s list of licensed cellular and gene therapy products checked on 28 October 2026 Approved cellular and gene therapy products. A trial registration or an investigational authorization is not marketing approval.

In Japan, the Act on Safety of Regenerative Medicine provides a framework that includes committee review, provision plans, and cell-processing requirements Index. A clinic’s provision plan is not a product marketing authorization or proof of clinical benefit. Product approval and its specific indication must be checked separately; PMDA publishes regulatory review reports 0004.

The PMDA English review-report collection is not a complete approval database, so absence from that page alone cannot prove that a product is unapproved. If a clinic says its DPSC treatment is “approved in Japan,” ask for the exact product name, approved indication, and official decision—not just a plan number. The site’s overview of Japan’s registration and compliance framework provides context, but an individual claim still needs its own regulatory documentation.

Ask whether the proposal describes an approved product, an investigational trial, or a paid clinical service under a provision plan. These are not equivalent evidence of benefit.

Risks and practical limits

Collecting cells from an extracted wisdom tooth still involves surgery. Possible problems include pain, swelling, dry socket, infection, and injury to nearby nerves. Nerve injury may cause numbness or tingling in the tongue, lips, or chin that can last weeks or months Wisdom tooth removal. Discuss whether extraction is needed for dental reasons before considering cell storage.

Processing introduces separate questions about cell identity, viability, sterility, and genetic stability. The 2017 pilot used controlled manufacturing and chromosome testing PMC5345141. Those safeguards do not make all commercial preparations equivalent, and using your own cells does not eliminate processing or procedural risks.

The 2025 report recorded toothache and injection-site swelling in cell recipients in the investigator-initiated trial, plus injection-site swelling in a saline recipient. The phase I trial also recorded gum swelling and diarrhea as possibly injection-related events. These were mild and resolved without treatment. No serious adverse events were reported over six months, but that does not establish long-term safety PMC12311062.

Delaying established dental care is another risk. Untreated periodontal disease can damage supporting bone and lead to tooth loss. Standard management includes infection control, professional cleaning, home care, and addressing risks such as smoking and diabetes Gum disease. In the 2025 study, cell injections followed scaling and root planing; they did not replace it PMC12311062.

Before paying for banking or treatment

Tooth banking

Ask whether a bank stores an intact tooth, pulp tissue, or isolated cells. Request its viability and sterility testing, release criteria, full storage and retrieval costs, and arrangements if the company closes. Preserving viable cells is a different question from proving that a future treatment will work. A storage contract should not be read as a promise of access to an approved therapy.

Reading a treatment proposal

Suppose a proposal uses the 2025 paper to advertise “1.67 mm of regeneration.” This is a hypothetical example, not a patient case. In that paper, 1.67 mm was mean attachment improvement in a post hoc stage III subgroup; saline recipients improved by 1.03 mm. The difference was 0.64 mm—not 1.67 mm of added benefit from the cells—and it was not a measure of a new tooth growing PMC12311062.

Take the proposal and the study to your dentist. Ask whether your diagnosis and disease stage match the study, whether the offered preparation and local delivery match, and whether standard periodontal care is included. A result from a selected subgroup does not predict your individual outcome.

Get the following in writing before making a decision:

  • The exact cell source and preparation: permanent-tooth pulp or another tissue, your own cells or a donor’s, cultured cells or mixed micrografts.
  • The dose, delivery site, treatment schedule, and accompanying standard care.
  • The legal status and supporting product authorization, trial documents, or provision-plan details.
  • The completed human evidence for the same preparation, condition, and delivery route—not just a trial registration or animal study.
  • The known risks, uncertainties, follow-up plan, total cost, and responsibility for complications.

A description of a stem-cell treatment process in Japan can help you organize logistical questions, but it cannot establish that the proposed DPSC treatment is effective or appropriate.

The short answer

Dental pulp stem cells are adult stem and stromal cells from permanent-tooth pulp with experimentally demonstrated regenerative properties. Selected human studies have tested pulp repair and periodontal treatment, but results depend on the preparation and procedure. They have not established whole-tooth replacement or a routine substitute for standard dental care. For a damaged tooth or gum disease, start with a dental examination rather than a promise of cell-based regeneration.

Have questions about a dental cell treatment proposal?

Contact us with general questions about consultations in Japan. Discuss the diagnosis, evidence, and treatment decision with your dentist.

Ask about consultations

This guide explains published research and regulatory information. It is not a diagnosis, a personal treatment recommendation, or a substitute for a dental examination.